News
Endeavour Cells investment in Cell2Cure
Cell2Cure has January 2024 received a significant equity investment from Endeavour Cell ApS, to further develop our...
Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases
In Europe, approximately 30 million people suffer from blindness and visual impairment. Rare Eye Diseases are a major...
Cell2Cure has treated the first patients with autism spectrum disorders and signs of leaky gut syndrome in a Phase I study
The first two children with autism spectrum disorder (ASD) and signs of leaky gut syndrome were treated October 2023...
The Cell2Cure core technology has been granted patent rights in Canada
As of the 18th of September 2023, the patent secures C2Cs technological concept for industrial production, upscaling,...
Cell2Cure researched by Tech Journal »Ingeniøren«
Cell2Cure has developed a stem cell product that does not require a tissue match between donor and patient and can...
Enrolment finalized in the lung transplantation ASC phase I-II clinical trial
Patient with severe terminal lung disease may ultimately be treated with a donor lung transplantation. However,...
Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)
The first patient with diabetic foot ulcer was treated with Cell2Cure’s allogeneic adipose tissue-derived mesenchymal...
The Danish Medicines Agency has approved the phase I clinical trial with cell treatment of children with autism and leaky gut syndrome
The Danish Medicines Agency has November 23rd, 2022, approved the un-blinded phase I dose-titrating clinical trial...
Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome
The Danish National Center for Ethics has November 2nd, 2022, approved the un-blinded phase I clinical trial with...
The Danish Medicines Agency has approved a Phase I study treating diabetic foot ulcer with C2C_ASC
Cell2Cure will be investigating treatment of patients with diabetic foot ulcus with C2C_ASC. The clinical study will...
The Cell2Cure core technology has been granted patent rights in Australia
As of the 24th of March 2022, the patent secures C2Cs technological concept for industrial production, upscaling, and...
Patient enrollment finalized in the Phase II trial testing ASC in Sjögren’s syndrome
Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and...
Publication of phase I results of ASC treatment of patients with radiation-induced Xerostomia
The objective of the phase I clinical trial was to evaluate safety and provide proof of concept for efficacy of...
Cell2Cure enters into a collaboration agreement with Endeavour Cells ApS
Cell2Cure has entered into a collaboration agreement with Endeavour Cells ApS, to collaborate on the preparation,...
Cell2Cure enters into a sublicense agreement with Endeavour Cells ApS
Cell2Cure has entered into a sublicense agreement with Endeavour Cells ApS, which will allow Endeavour Cells ApS to...
Collaboration agreement between Cell2Cure and Cbio A/S
Cell2Cure (C2C) has entered into a collaboration agreement with Cbio A/S to establish C2C´s own GMP facility for...
ASC’s enter Phase II testing in Salivary gland re-generation
Patients with head-and neck cancer are often treated with radiation therapy. A side-effect to this life saving therapy...
CSCC´s ASC Heart failure study completed
Heart failure is a serious condition with a high morbidity and mortality. The patient enrolment and 1 year follow-up...
Cell2Cure in a Lung Transplantation study
Lung transplantation is the ultimate treatment of patients with severe lung disease. However, the short- and long-term...
Cell2Cure is part of testing ASC’s to reestablish nerve conduction in the heart
The nerve conduction system within the heart can be destroyed by a process involving increased fibrosis and...
ASC’s enter Phase II testing in Sjögren’s syndrome
Sjögren's syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear...
Cell2Cure partner in a new Stem Cell Center
Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center, CSIC, receives funding from...
Publication of phase I trial results – ASC treatment in Sjögren’s syndrome
The clinical phase I study evaluated the safety and feasibility of injecting allogeneic adipose-derived mesenchymal...
CONTACT US
Innobooster grant
SME Instrument grant
This project has received funding from the European Union’s SME Instrument, Horizon 2020 research and innovation programme under grant agreement No [H2020-SMEINST-868284_PRO-SCT]
Grand Solution Grant
Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center, CSIC, receives funding from Innovation Fund Denmark.